AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19349312 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 1 microg/kg intravenously
Number of subjects: 100
Study 16917445 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine administration (0.4 gr/kg daily for 6 months)
Number of subjects: 39
Study 15123958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy for 1 hour (Group 1: first hour, Group 2: second hour)
Number of subjects: 16
Study 15123958 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (first hour)
Number of subjects: 16
Study 15123958 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (second hour)
Number of subjects: 16
Study 15123958 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy
Number of subjects: 16
Study 11899785 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen
Number of subjects: 2368
Study 11899785 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2368
Study 9143434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment in patients with WMLA
Number of subjects: 72
Study 9143434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment in patients without WMLA
Number of subjects: 72
Study 7968872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine or nitrendipine (3 to 6 month treatment)
Number of subjects: 26
Study 7968872 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 26
Study 3609121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim suspension 3 mg/kg (fasting)
Number of subjects: 12
Study 3609121 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim suspension 3 mg/kg (with food)
Number of subjects: 12
Study 3609121 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim suspension 3 mg/kg (with food and guar)
Number of subjects: 12
Study 30113195 — intervention group
Group type: EXPERIMENTAL
Intervention: Default opt-in system
Number of subjects: 0
Study 30113195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated choice system
Number of subjects: 0
Study 30113195 — intervention group
Group type: COMPARATOR
Intervention: Default opt-out system
Number of subjects: 0
Study 30113195 — intervention group
Group type: COMPARATOR
Intervention: Mandatory donor system
Number of subjects: 0
Study 28851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Client Care (ICC) intervention for diabetic foot ulcers
Number of subjects: 14017
Study 28851413 — intervention group
Group type: COMPARATOR
Intervention: Control for diabetic foot ulcers
Number of subjects: 14017
Study 28851413 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Client Care (ICC) intervention for pilonidal sinus
Number of subjects: 14017
Study 28851413 — intervention group
Group type: COMPARATOR
Intervention: Control for pilonidal sinus
Number of subjects: 14017
Study 26582972 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐GPC (600 mg per day)
Number of subjects: 13
Study 26582972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23684633 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in motivational interviewing (MI)
Number of subjects: 0
Study 20595156 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels
Number of subjects: 925
Study 20595156 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) tiers
Number of subjects: 925
Study 20595156 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 925
Study 18495508 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60mg every 6 months
Number of subjects: 39
Study 18495508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70mg once weekly
Number of subjects: 39
Study 18495508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16626981 — intervention group
Group type: COMPARATOR
Intervention: 1 mM BMTd lotion applied twice daily for 14 days
Number of subjects: 26
Study 16626981 — intervention group
Group type: COMPARATOR
Intervention: 2 mM BMTd mixture applied for 7 days
Number of subjects: 26
Study 16626981 — intervention group
Group type: COMPARATOR
Intervention: 2 mM BMTd mixture applied 30 min before a cold challenge
Number of subjects: 26
Study 16626981 — intervention group
Group type: COMPARATOR
Intervention: 1 mM BMTd lotion applied twice daily for 2 weeks to one eye
Number of subjects: 26
Study 16626981 — intervention group
Group type: COMPARATOR
Intervention: 2 mM BMTd lotion applied to lips
Number of subjects: 26
Study 14687475 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (200 micro s pulses at 100 Hz and 2 ‐ 3 times sensory threshold)
Number of subjects: 20
Study 14687475 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study 10997370 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 10 mg/kg/d
Number of subjects: 12
Study 10997370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8959999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) therapy
Number of subjects: 88
Study 8959999 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (sham US)
Number of subjects: 88
Study 1327697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative radiotherapy plus surgery (RS)
Number of subjects: 423
Study 1327697 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus postoperative chemotherapy (SC)
Number of subjects: 423
Study 1327697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery followed by postoperative chemotherapy (RSC)
Number of subjects: 423
Study 1327697 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 423
Study 3906516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal D-Ala2-D-Leu5-enkephalin (DADL)
Number of subjects: 10
Study 3906516 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine sulfate (MS)
Number of subjects: 10
Study 30664397 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Physical Exercise and Dietary therapy (PED‐t)
Number of subjects: 15
Study 29980181 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented RCT populations (including patients with one or two of the specified characteristics)
Number of subjects: 0
Study 29980181 — intervention group
Group type: COMPARATOR
Intervention: Typical RCT population (defined with typical exclusion criteria)
Number of subjects: 0
Study 27452293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (NaOCl)
Number of subjects: 49
Study 27452293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 49
Study 27452293 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide medication
Number of subjects: 49
Study 27452293 — intervention group
Group type: COMPARATOR
Intervention: Both NaOCl and CHX
Number of subjects: 49
Study 24606590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Number of subjects: 300
Study 24606590 — intervention group
Group type: COMPARATOR
Intervention: Health & Wellness (control) Intervention
Number of subjects: 300
Study 21951980 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment (up to 6 months)
Number of subjects: 48
Study 20227062 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias manipulation
Number of subjects: 83
Study 17389537 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative feedback reports (6 quarterly reports over 18 months)
Number of subjects: 308
Study 17389537 — intervention group
Group type: COMPARATOR
Intervention: General reminders
Number of subjects: 308
Study 17389537 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone referrals
Number of subjects: 308
Study 17389537 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback practices
Number of subjects: 308
Study 17389537 — intervention group
Group type: COMPARATOR
Intervention: Gentle reminder practices
Number of subjects: 308
Study 15610946 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 111
Study 15610946 — intervention group
Group type: EXPERIMENTAL
Intervention: galantamine
Number of subjects: 111
Study 15610946 — intervention group
Group type: EXPERIMENTAL
Intervention: rivastigmine
Number of subjects: 111
Study 15610946 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 111
Study 12002555 — intervention group
Group type: EXPERIMENTAL
Intervention: Center- and home-based health promotion programs
Number of subjects: 0
Study 12002555 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment methods
Number of subjects: 0
Study 12002555 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment costs
Number of subjects: 0
Study 12002555 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection criteria and frailty status
Number of subjects: 0
Study 12002555 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies
Number of subjects: 0
Study 10102587 — intervention group
Group type: EXPERIMENTAL
Intervention: IAN block + intraosseous injection of 1.8 mL of 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 40
Study 10102587 — intervention group
Group type: COMPARATOR
Intervention: IAN block + intraosseous injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 10102587 — intervention group
Group type: COMPARATOR
Intervention: IAN block + mock intraosseous injection
Number of subjects: 40
Study 10102587 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate increase with intraosseous injection of mepivacaine and lidocaine
Number of subjects: 40
Study 7873114 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise coaching for 3 months
Number of subjects: 20
Study 7873114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise coaching)
Number of subjects: 20
Study 2116260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin monotherapy (5 mg, 10 mg, and 20 mg twice daily)
Number of subjects: 33
Study 2116260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin with cholestyramine therapy
Number of subjects: 33
Study 1275001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation group
Number of subjects: 45
Study 1275001 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 45
Study 1275001 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 31638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music Therapy (GMT) combined with Treatment as Usual (TAU)
Number of subjects: 60
Study 31638882 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) only
Number of subjects: 60
Study 30711463 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered dietitian nutritionist-led telemedicine program
Number of subjects: 118
Study 30711463 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 28625255 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 treatment group (supplemented 300 kU vitamin D3)
Number of subjects: 57
Study 28625255 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (injected 1 mL physiological saline)
Number of subjects: 57
Study 28625255 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 treatment group
Number of subjects: 57
Study 28625255 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 57
Study 27352341 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sedation therapy with midazolam
Number of subjects: 104
Study 27352341 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 104
Study 23911266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 452
Study 23911266 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 452
Study 22013734 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 million of Lactobacillus bulgaricus and Streptococcus thermophilus per day
Number of subjects: 30
Study 22013734 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (120 mg of starch)
Number of subjects: 30
Study 19754998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed toolkit including professional guidelines, BMI calculation tool, growth charts, and educational information.
Number of subjects: 0
Study 19754998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no toolkit received).
Number of subjects: 0
Study 18036708 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA) vaccine administered at Study Days 0 and 28 by subcutaneous or intramuscular injection
Number of subjects: 90
Study 18036708 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA) vaccine
Number of subjects: 90
Study 18036708 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE vaccination prior to Dryvax
Number of subjects: 90
Study 18036708 — intervention group
Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 90
Study 15023585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus olanzapine (5-10 mg, mean 6.1 mg)
Number of subjects: 44
Study 15023585 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 44
Study 14714042 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice per week subcutaneously)
Number of subjects: 71
Study 10215295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 88
Study 10215295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving NSAIDs)
Number of subjects: 88
Study 7880782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.006% latanoprost given twice daily
Number of subjects: 50
Study 7880782 — intervention group
Group type: COMPARATOR
Intervention: Placebo given at 8 am and latanoprost at 8 pm for 3 months
Number of subjects: 50
Study 2233599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 10
Study 2233599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27372 — intervention group
Group type: EXPERIMENTAL
Intervention: Camazepam
Number of subjects: 31
Study 27372 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 31
Study 31315150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude journalling intervention (8 weeks)
Number of subjects: 80
Study 31315150 — intervention group
Group type: COMPARATOR
Intervention: Standard care (8 weeks)
Number of subjects: 80
Study 31443726 — intervention group
Group type: COMPARATOR
Intervention: Control group (originally planned cohort)
Number of subjects: 509
Study 31443726 — intervention group
Group type: COMPARATOR
Intervention: Control group (all randomized cohort)
Number of subjects: 509
Study 28365444 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict gluten-free diet
Number of subjects: 200
Study 28365444 — intervention group
Group type: COMPARATOR
Intervention: Non-adherence to gluten-free diet
Number of subjects: 200
Study 28365444 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled challenge
Number of subjects: 200
Study 26062190 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking before operation combined with paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Number of subjects: 80
Study 26062190 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Number of subjects: 80
Study 23578667 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction spectrum imaging cellularity maps
Number of subjects: 12
Study 23578667 — intervention group
Group type: COMPARATOR
Intervention: ADC
Number of subjects: 12
Study 23578667 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 12
Study 21455007 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily glycerin suppository (250 mg for 24‐27(+6) weeks subgroup or 500 mg for 28‐31(+6) weeks subgroup) for 10 days from 24 hours of age
Number of subjects: 54
Study 21455007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 21455007 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily glycerin suppository
Number of subjects: 54
Study 18507650 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/l GOS/FOS in a 9 : 1 ratio (IMMUNOFORTIS)
Number of subjects: 84
Study 18507650 — intervention group
Group type: COMPARATOR
Intervention: 8 g/l maltodextrine (placebo)
Number of subjects: 84
Study 17692729 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-prebiotic complex treatment
Number of subjects: 25
Study 17692729 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 weeks after crossover to treatment)
Number of subjects: 25
Study 15051746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran + Alcohol (0.5 g/kg for women, 0.6 g/kg for men)
Number of subjects: 26
Study 15051746 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran alone
Number of subjects: 26
Study 15051746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran + Alcohol
Number of subjects: 26
Study 11429716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oracol
Number of subjects: 143
Study 11429716 — intervention group
Group type: EXPERIMENTAL
Intervention: OraSure
Number of subjects: 143
Study 11429716 — intervention group
Group type: COMPARATOR
Intervention: Omni‐SAL
Number of subjects: 143
Study 9924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 5 mg ml‐1
Number of subjects: 100
Study 9924220 — intervention group
Group type: COMPARATOR
Intervention: Isobaric bupivacaine 5 mg ml‐1
Number of subjects: 100
Study 9924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Isobaric and Hyperbaric bupivacaine)
Number of subjects: 100
Study 7800402 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (30 cc of 0.25% bupivacaine with 1:200,000 epinephrine)
Number of subjects: 81
Study 7800402 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg in 28 cc normal saline, total volume 30 cc)
Number of subjects: 81
Study 30584113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity aquatic exercise training
Number of subjects: 89
Study 30584113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity + upper extremity and trunk aquatic exercise training
Number of subjects: 89
Study 30584113 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 89
Study 28574180 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion with Equol powder (Isoflavandiol‐E‐55‐RS®)
Number of subjects: 64
Study 28574180 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion with microencapsulated Equol (Vesisorb® Isoflavandiol‐E‐55‐RS®)
Number of subjects: 64
Study 28574180 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion with lecithin (Vesisorb® placebo)
Number of subjects: 64
Study 28574180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 24963830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based training intervention (ACTr)
Number of subjects: 0
Study 24963830 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation Training (PETr)
Number of subjects: 0
Study 23541330 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 14
Study 23541330 — intervention group
Group type: COMPARATOR
Intervention: Normal Gravity (NG)
Number of subjects: 14
Study 21547878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 108
Study 21547878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation in patients with minimal hepatic encephalopathy (MHE; n=64)
Number of subjects: 108
Study 21547878 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical flicker frequency (CFF) assessment
Number of subjects: 108
Study 21547878 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF in patients with CFF < 38 Hz
Number of subjects: 108
Study 18539406 — intervention group
Group type: COMPARATOR
Intervention: Long-course radiotherapy (RT)
Number of subjects: 231
Study 18539406 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy (RT)
Number of subjects: 231
Study 16649506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home
Number of subjects: 2048
Study 16649506 — intervention group
Group type: COMPARATOR
Intervention: Continued care in an acute hospital
Number of subjects: 2048
Study 15130916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) (estrogen plus progestin)
Number of subjects: 0
Study 15130916 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 0
Study 10757383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic aorto-femoral bypass grafting procedure
Number of subjects: 41
Study 10757383 — intervention group
Group type: COMPARATOR
Intervention: Conventional bypass grafting procedure
Number of subjects: 41
Study 9069481 — intervention group
Group type: EXPERIMENTAL
Intervention: Right sided lesions
Number of subjects: 31
Study 9069481 — intervention group
Group type: EXPERIMENTAL
Intervention: Left sided lesions
Number of subjects: 31
Study 9069481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 8379860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran injections (5 injections spaced 4 weeks)
Number of subjects: 100
Study 8379860 — intervention group
Group type: COMPARATOR
Intervention: Iron with folic acid orally
Number of subjects: 100
Study 3093556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 2 mg
Number of subjects: 8
Study 3093556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 10 mg
Number of subjects: 8
Study 3093556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 20 mg
Number of subjects: 8
Study 3093556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29525076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213
Study 29525076 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study 27475339 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programme (on-the-job training 20 hours and two workshops 8 hours)
Number of subjects: 925